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We examined fecal samples from 6,774 patients with 
enteritis in Belgium, 2008–2013.  Members of the genus 
Arcobacter were the fourth most common pathogen group 
isolated, and the isolation rate was higher than previously 
reported. Culturing Arcobacter in a microbiology labora-
tory is feasible and should thus be tested for in cases of 
diarrheal disease. 
Campylobacteriosis is the most frequently reported zoonosis in industrialized countries with an increas-
ing incidence during 2007–2011 (1). In this study, bacte-
ria of the Arcobacter genus, which is closely related to the 
Campylobacter genus, comprised the fourth most common 
pathogenic group isolated from stool specimens of patients 
with acute enteritis in Ghent, Belgium.
Bacteria species of the genus Arcobacter were first 
isolated from aborted bovine and porcine fetuses in 1977 
(2). Based on similar phenotypic characteristics, they 
were originally classified as aerotolerant Campylobacter 
spp., until a separate genus was introduced in 1991 (2). 
Since then, 18 species have been identified and new spe-
cies are pending. Members of the genus Arcobacter are 
aerotolerant gram-negative bacteria and able to grow at 
temperatures <30°C, which differentiate them from the 
Campylobacter species. The species A. butzleri, A. cry-
aerophilus, A. skirrowii, A. cibarius, A. thereius, and 
A. trophiarum have been identified in livestock world-
wide and have been isolated from food of animal ori-
gin. Though these species have been associated with ill-
ness in farm animals, they are also known to colonize 
healthy animals (3).
Arcobacter have been classified as emergent patho-
gens by the International Commission on Microbial Spec-
ifications for Foods (4). Currently, 3 species have been 
reported to infect humans. Contaminated drinking water 
and raw or undercooked food that is eaten or handled are 
the most frequent sources of human infection (5,6). An 
association of A. butzleri and A. cryaerophilus with en-
teritis, colitis, and septicemia has been proposed in epi-
demiologic studies, outbreak reports, and case reports (7), 
although A. cryaerophilus can also be present in healthy 
humans (8). More recently, A. skirrowii has been impli-
cated as the causal agent of bacteremia and colitis in indi-
vidual case reports (9).
Information about transmission, colonization in the 
gut, and virulence in humans of members of the Arcobacter 
genus is insufficient. The presence of virulence genes and 
their distribution within the genus have been proven, but 
their role in pathogenicity in selected host groups has not 
yet been demonstrated (10).
Most laboratories do not use appropriate culture 
methods or conditions to detect species other than Cam-
pylobacter jejuni and C. coli from feces. Furthermore, 
identification of Campylobacter and related organisms 
to species level is not always performed or is executed 
with phenotypic methods, leading to conflicting results. 
Hence, data on the incidence and clinical importance of 
Arcobacter remain scarce. The aims of this study were 
to assess the feasibility of Arcobacter culture in a clini-
cal microbiology laboratory and to determine the recent 
prevalence of Arcobacter spp. in humans with gastroin-
testinal disease in Belgium.
The Study
Fecal samples were collected from outpatients and 
patients with symptoms of enteritis who were admit-
ted for <72 hours to the Sint-Lucas Hospital in Ghent, 
Belgium, during 2008–2013. All age groups were repre-
sented. We examined the fecal samples macroscopically 
for consistency and presence of blood and mucus and 
microscopicallyfor leukocytes and cultured them for all 
common bacterial pathogens. Feces of patients <2 years 
of age were also tested for rotavirus and enteric adeno-
virus, and those of adult patients with loose or mucous-
containing stools were also tested for toxigenic Clostridi-
um difficile. Samples were tested for parasites on clinical 
demand only.
We cultured for Arcobacter using  an isolation meth-
od for fecal samples carried out in veterinary medicine 
that was previously validated for use on human feces 
(11): 1 g of feces was inoculated into a liquid selective 
broth (24 g/L Arcobacter broth with 50 mL lysed, defibri-
nated horse blood and an antimicrobial supplement of 16 
mg/L cefoperazone, 10 mg/L amphotericin B, 100 mg/L 
5-fluorouracil, 64 mg/L trimethoprim, and 32 mg/L novo-
biocine [Oxoid, Cambridge, United Kingdom]) and incu-
bated for 24 h at 25°C in a microaerobic atmosphere of 6% 
O2, 7% CO2, 7% H2, and 80% N2 (Advanced Instruments, 
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Inc., Norwood, MA, USA). Then, 40 μL of enriched broth 
was plated onto a solid Arcobacter-selective medium with 
the same composition as the broth but with the addition of 
12 g/L agar technical no. 3 (Oxoid) and without the horse 
blood. The plates were incubated for 72 h at 25°C in a 
microaerobic atmosphere and examined daily. Arcobacter 
colonies were detected by screening the selective trans-
parent agar as described with Henry transillumination mi-
croscopy for bluish colonies (11). Definitive identification 
was performed by a genus- and species-specific multiplex 
PCR, and subsequently, by amplification fragment length 
polymorphism (12,13).
Of the 8,994 eligible samples received during the 
study period, 6,774 (75.31%) samples were cultured for 
Arcobacter; 2,220 samples (24.68%) were excluded be-
cause of insufficient sample size. Of samples from the 
study population, Campylobacter spp. were isolated in 
380 (5.61%), Salmonella spp. in 138 (2.04%), toxigenic 
C. difficile in 109 (1.61%), Aeromonas spp. in 16 (0.24%), 
and Yersinia enterocolitica in 13 (0.19%). Other gastro-
intestinal pathogens isolated in lower numbers included 
Shigella spp. (9 samples, 0.13%) and Plesiomonas spp. (3 
samples, 0.05%).
Arcobacter spp. were isolated in samples from 89 pa-
tients (1.31%), ranking members of this genus as the fourth 
most commonly isolated pathogen group in the study. This 
ranking is comparable to those of other reports, although a 
higher isolation rate was obtained during this study (14,15). 
The distribution frequency of pathogens and of A. butzleri 
versus A. cryaerophilus, 49 (0.72%) and 38 (0.56%) iso-
lates, respectively, is shown in Table 1. A. skirrowii was 
not recovered, but the first 2 known isolates of A. thereius 
(0.03%) from humans were documented. In the excluded 
population (n = 2,220), comparable recovery rates of Cam-
pylobacter spp. (6.53%), Salmonella spp. (2.88%) and 
C. difficile (2.07%) were observed. In 6 patients whose 
samples were positive for Arcobacter, a second pathogen 
was isolated: 1 patient was positive for Salmonella spp., 
samples from 2 patients showed Campylobacter spp. and 
A. butzleri, and toxigenic C. difficile was detected in 2 pa-
tients who tested positive for A. butzleri and in 1 patient 
who tested positive for A. cryaerophilus.
We collected retrospective data about age, hospital 
stay, presence of diarrhea, clinical diagnosis of enteri-
tis, colonoscopy results, and underlying disease for the 
positive-culture patient group. We assessed differences 
between study populations and results using t-test and Χ2 
statistical methods as appropriate.
The mean age of the included population (29 years) 
differed significantly (p<0.01) from the excluded group (22 
years), because of an excess of infants from whom sample 
material was insufficient in the latter group. The positive-
culture patient group had a mean age of 42 years and 
demonstrated a significantly older age distribution pattern 
(p<0.01) (Figure). The consistency of fecal samples was 
not predictive (p = 0.62) for the presence of Arcobacter. 
Within the Arcobacter-positive group, the mean age of 
patients whose specimens shed A. butzleri (49 years) was 
significantly higher (15 years, p<0.01) than that of patients 
whose specimens shed A. cryaerophilus (34 years). Pres-
ence of A. butzleri in patients admitted to the hospital and 
in outpatients was not significantly linked with underlying 
disease (p = 0.12). A. cryaerophilus was more frequently 
observed in outpatients who had uncomplicated gastroen-
teritis than in hospitalized patients with coexisting condi-
tions (p<0.001) (Table 2).
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Table	1. Distribution	of	study	population	and	number	(%)	of	bacterial	gastrointestinal	pathogens	during	the	study	periods 2008–2010 
and 2012–2013, Belgium* 
Characteristics 2008	(%) 2009	(%) 2010	(%) 2012	(%) 2013	(%) 5-y	period	(%) 
Eligible samples 1,819 1,843 1,612 2,229 1,491 8,994 
 Included 1,375	(76) 1,374	(75) 1,112	(69) 1,768	(79) 1,145	(77) 6,774	(75) 
 Excluded 444	(24) 469	(25) 500	(31) 461	(21) 346	(23) 2,220	(25) 
Pathogens	identified       
 Included patients       
  Campylobacter spp. 64	(4.7) 54	(3.9) 68	(6.1) 85	(4.8) 109	(9.5) 380	(5.6) 
  Salmonella spp. 29	(2.1) 32	(2.3) 28	(2.5) 26	(1.5) 23	(2.0) 138	(2.0) 
  Clostridium difficile† 26	(1.9) 19	(1.4) 17	(1.5) 18	(1.0) 29	(2.5) 109	(1.6) 
  Arcobacter spp. 18	(1.3) 12	(0.9) 18	(1.6) 17	(0.9) 24	(2.1) 89	(1.3) 
  Arcobacter butzleri 6	(0.4) 7	(0.5) 11	(0.9) 7	(0.4) 18	(1.6) 49	(0.7) 
  Arcobacter cryaerophilus 12	(0.9) 5	(0.4) 5	(0.4) 10	(0.7) 6	(0.5) 38	(0.6) 
  Arcobacter thereius 0 0 2	(0.1) 0 0 2	(0.03) 
  Aeromonas spp. 2	(0.1) 3 (0.2) 6	(0.5) 1	(0.1) 4	(0.3) 16	(0.2) 
  Yersinia enterocolitica 1	(0.1) 4	(0.3) 1	(0.1) 2	(0.1) 5	(0.4) 13	(0.2) 
  Shigella spp. 2	(0.1) 2	(0.1) 3	(0.3) 2	(0.1) 0 9	(0.1) 
  Plesiomonas spp 0 2	(0.1) 0 0 1	(0.1) 3	(0.04) 
 Excluded patients  
  Campylobacter spp. 20	(4.5) 23	(4.9) 39	(7.8) 27	(5.9) 36	(10.4) 145	(6.5) 
  Salmonella spp. 20	(4.5) 14	(3.0) 15	(3.0) 11	(2.4) 4	(1.2) 64	(2.9) 
  Clostridium difficile† 8	(1.8) 16	(3.4) 7	(1.4) 8	(1.7) 7	(2.0) 46	(2.1) 
*The	study	was	interrupted	for	1 y in 2011. 
†Toxigenic strains only. 
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Conclusions
Arcobacter species were the fourth most common 
pathogen group isolated from fecal samples from persons 
with acute enteric disease. The high isolation rate could 
possibly be explained by the inclusion of an outpatient 
population, local indications for sampling, and the use of 
an enrichment culture method. The Arcobacter-positive 
patients tended to belong to older age groups. No notable 
association of A. butzleri enteritis with coexisting condi-
tions was observed. The feasibility of selective culturing 
Arcobacter from fecal material in a routine microbiology 
hospital laboratory was confirmed, but the slow turnaround 
times for culture results show a need for optimization of 
methods. Arcobacter species should be considered and 
tested for in cases of diarrheal disease.
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